ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1094

Extremely Elevated Erythrocyte Sedimentation Rate Revisited in Rheumatic Diseases: Flare-Up or Infection? Single Centre Retrospective Analysis

Emre Bilgin1, Zehra Ozsoy2, Melek Seren Aksun3, İmdat Eroğlu3 and Umut Kalyoncu1, 1Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 2Division of Rheumatology, Department of Internal Medicine, Hacettepe University, Ankara, Turkey, 3Department of Internal Medicine, Hacettepe University, Ankara, Turkey

Meeting: ACR Convergence 2021

Keywords: erythrocyte sedimentation rate, flare-up, Infection, Rheumatic diseases

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: To compare the laboratory characteristics of patients who had rheumatic diseases and presented with extremely elevated ESR (≥100 mm/h) and had either disease flare-up or documented infection and to find factors which may help to differentiate patients with disease flare-up and infection.

Methods: In this retrospective analyses, patients -either inpatient or outpatient- with ESR≥100 mm/h between 2015 and 2020 were identified. Patients with a certain diagnosis of inflammatory rheumatic disease and had either disease flare-up or documented infection were included in the analysis. Flare-up was defined as need of newly prescribed immunosuppressive (IS) agents or increment of dose of the already prescribed IS agents and NOT prescription of any kind of antibiotics. Infection was defined as documentation of possible infective agent via culture or imaging finding AND prescription of any kind of antibiotics. Available laboratory data temporarily nearest to ESR≥100 mm/h were recorded. Decision tree by R (package party) was used to construct a clinician-friendly algorithm for the discrimination of disease flare-up and infection by using routine laboratory tests.

Results: Of 311 patients with ESR≥100 mm/h and rheumatic diseases, 225 were included. 111 (49.3%) patients had disease flare-up and 114 (50.7%) patients had infection. In flare-up group, 93 (83.8%) had inflammatory arthritis [57 RA, 31 SPA, 2 JIA, 2 crystal arthritis, 1 adult Still’s disease], 11 (9.9%) had vasculitis [5 large-vessel, 4 small-vessel, 2 PMR] , 7 (6.3%) had connective tissue disorder (CTD) [5 SLE, 1 overlap syndrome and 1 SSc]; however, in infection group 65 (57.0%) had inflammatory arthritis [25 RA, 22 SpA, 6 crystal arthritis, 6 FMF, 4 adult Still’s disease, 2 JIA], 22 (19.3%) had vasculitis [12 small-vessel, 5 large-vessel vasculitis, 2 PMR, 1 relapsing polychondritis, 1 Behcet’s syndrome and 1 PAN] and 27 (23.7%) had CTD [12 SLE, 5 SSc, 3 Sjögren’s syndrome, 3 sarcoidosis, 2 myositis, 1 retroperitoneal fibrosis, 1 granulomatous mastitis]. Thrombocyte, MCV, albumin and total protein were significantly lower in infection group, however; neutrophil, MPV, CRP and ferritin were significantly lower in flare-up group (Table). Lipids, vitamin B12 and complement levels were similar. In decision tree, serum albumin ≤2.78 g/dl was the first branch (89.1% for infection vs. 10.9 for flare-up). If serum albumin >2.78 g/dl, thrombocyte ≤290/mm6 was the second branch (thrombocyte count≤290/mm6; 69.2% for infection vs. 30.8% for flare-up // thrombocyte >290/mm6; 32.9% for infection vs. 67.1% for flare-up) (Figure). In multivariable analysis factors were associated with infection over flare-up (reference level): thrombocyte count (per 1/mm6 increment) (aOR: 0.997 (0.995-0.999)), albumin (per 1 gr/dl increment) (aOR: 0.37 (0.22-0.63)), CRP (1 mg/dl increment) (aOR: 1.044 (1.011-1.044)).

Conclusion: Extremely elevated ESR is an alarming finding for clinicians who follow-up patients with rheumatic diseases. Flare-up of the underlying rheumatic disease and infections should be kept in mind in patients with such presentation. We have generated a simple and clinician-friendly decision tree in which albumin level and thrombocyte count were key elements.


Disclosures: E. Bilgin, None; Z. Ozsoy, None; M. Aksun, None; . Eroğlu, None; U. Kalyoncu, None.

To cite this abstract in AMA style:

Bilgin E, Ozsoy Z, Aksun M, Eroğlu , Kalyoncu U. Extremely Elevated Erythrocyte Sedimentation Rate Revisited in Rheumatic Diseases: Flare-Up or Infection? Single Centre Retrospective Analysis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/extremely-elevated-erythrocyte-sedimentation-rate-revisited-in-rheumatic-diseases-flare-up-or-infection-single-centre-retrospective-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/extremely-elevated-erythrocyte-sedimentation-rate-revisited-in-rheumatic-diseases-flare-up-or-infection-single-centre-retrospective-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology